You are now leaving a non-prescription product website and entering a prescription only product website.
Carlsbad, CA – February 21, 2012 – SkinMedica, Inc., the fastest growing professional skin care company in the U.S., today announced that the Company’s Chief Financial Officer, Steve Loomis, will present at the Citi 2012 Global Health Care Conference on Tuesday, February 28, 2012 at 3:00 p.m. EST at The Waldorf=Astoria Hotel in New York City. This presentation will not be webcast.
Investor Relations Contact:
Stern Investor Relations, Inc.
SkinMedica, Inc. is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica’s clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. Colorescience Pro’s dermatologist recommended, high-performance cosmetics are formulated to remedy and camouflage specific skin concerns and protect skin from damaging effects of the sun and environment. Colorescience Pro’s luxury aesthetic makeup line is sold in the physician and medical spa channels.
TNS Recovery Complex®, VANIQA®, and SkinMedica®, are registered trademarks of SkinMedica, Inc and affiliates.